1,727 reports of this reaction
5.8% of all DORNASE ALFA reports
#2 most reported adverse reaction
CYSTIC FIBROSIS is the #2 most commonly reported adverse reaction for DORNASE ALFA, manufactured by Genentech, Inc.. There are 1,727 FDA adverse event reports linking DORNASE ALFA to CYSTIC FIBROSIS. This represents approximately 5.8% of all 29,815 adverse event reports for this drug.
Patients taking DORNASE ALFA who experience cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTIC FIBROSIS is moderately reported among DORNASE ALFA users, representing a notable but not dominant share of adverse events.
In addition to cystic fibrosis, the following adverse reactions have been reported for DORNASE ALFA:
The following drugs have also been linked to cystic fibrosis in FDA adverse event reports:
CYSTIC FIBROSIS has been reported as an adverse event in 1,727 FDA reports for DORNASE ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTIC FIBROSIS accounts for approximately 5.8% of all adverse event reports for DORNASE ALFA, making it one of the most commonly reported side effect.
If you experience cystic fibrosis while taking DORNASE ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.